Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) shares traded 39.63% higher at $9.09 on Wall Street last session.
In accordance with the data, 3 analysts cover Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $240.00 and a low of $24.00, we find $132.00. Given the previous closing price of $6.51, this indicates a potential upside of 1927.65 percent. QNRX stock price is now 52.57% away from the 50-day moving average and -31.61% away from the 200-day moving average. The market capitalization of the company currently stands at $8.97M.
It has been rated a hold by 1 analysts and a buy by 2. Brokers who have rated the stock have averaged $132.00 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in QNRX stock. A new stake in Quoin Pharmaceuticals Ltd. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $112,000. RENAISSANCE TECHNOLOGIES LLC invested $11,000 in shares of QNRX during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in Quoin Pharmaceuticals Ltd. valued at approximately $5,000.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) opened at $7.29 on Friday. During the past 12 months, Quoin Pharmaceuticals Ltd. has had a low of $5.04 and a high of $337.32. As of last week, the company has a debt-to-equity ratio of 0.38, a current ratio of 4.20, and a quick ratio of 4.20. The fifty day moving average price for QNRX is $6.02 and a two-hundred day moving average price translates $13.20 for the stock.
The latest earnings results from Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$4.08, missing analysts’ expectations of -$3.39 by -0.69. This compares to -$2.51 EPS in the same period last year. The company reported revenue of $2.78 million for the quarter, compared to $2.18 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.57 percent.
Quoin Pharmaceuticals Ltd.(QNRX) Company Profile
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.
